SEC Tracker
Get the app
8-K item 3.01

Exchange deficiency notices

Open Nasdaq and NYSE listing deficiency notices and their cure deadlines as stated in the filing.

Open notices by deadline 54

CompanyRuleNoticeCure byFiling
Skye BioscienceSKYEfloat $130MStockholders' equity too lowNasdaq rule 5450(b)(1)(A)May 15, 2026 (8-K filed)Nov 9, 20268-K item 3.01
Rani Therapeutics HoldingsRANIfloat $65.0MStock under $1Nasdaq rule 5450(a)(1)May 11, 2026Nov 9, 20268-K item 3.01
GT BiopharmaGTBPfloat $8.6MStock under $1Nasdaq rule 5550(a)(2)May 20, 2026Nov 16, 20268-K item 3.01
Medicus PharmaMDCXfloat $28.3MMarket value too lowNasdaq rule 5550(b)(2)May 20, 2026Nov 16, 20268-K item 3.01
iSpecimenISPCListing ruleNasdaq rule 5550(b)Sep 8, 2026Nov 25, 20268-K item 3.01
aTYR PHARMAATYRfloat $464MStock under $1Nasdaq rule 5550(a)(2)Jun 3, 2026Nov 30, 20268-K item 3.01
Jasper TherapeuticsJSPRfloat $74.8MStock under $1Nasdaq rule 5550(a)(2)Jun 3, 2026Nov 30, 20268-K item 3.01
SoligenixSNGXfloat $4.6MStock under $1Nasdaq rule 5550(a)(2)Jun 10, 2026Dec 7, 20268-K item 3.01
CelularityCELUfloat $28.4MMarket value too lowNasdaq rule 5550(b)(2)Jun 9, 2026Dec 7, 20268-K item 3.01
Heron TherapeuticsHRTXfloat $235MStock under $1Nasdaq rule 5550(a)(2)Jun 25, 2026Dec 22, 20268-K item 3.01
PluriPLURfloat $15.2MMarket value too lowNasdaq rule 5550(b)(2)Jul 7, 2026Jan 4, 20278-K item 3.01
Actuate TherapeuticsACTUfloat $42.1MMarket value too lowNasdaq rule 5450(b)(2)(A)Jul 15, 2026Jan 11, 20278-K item 3.01
VivoSim LabsVIVSfloat $7.5MStockholders' equity too lowNasdaq rule 5550(b)(1)Jul 20, 2026Jan 16, 20278-K item 3.01
Oncolytics BiotechONCYfloat $72.1MStock under $1Nasdaq rule 5550(a)(2)Jul 24, 2026 (8-K filed)Jan 19, 20278-K item 3.01
Standard BiotoolsLABfloat $291MStock under $1Nasdaq rule 5450(a)(1)Jul 22, 2026Jan 19, 20278-K item 3.01
Cypherpunk TechnologiesCYPHfloat $12.1MStock under $1Nasdaq rule 5550(a)(2)Jul 21, 2026 (8-K filed)Jan 19, 20278-K item 3.01
CelularityCELUfloat $28.4MStock under $1Nasdaq rule 5450(a)(1)Jul 23, 2026Jan 19, 20278-K item 3.01
InvivydIVVDfloat $50.9MStock under $1Nasdaq rule 5450(a)(1)Jul 23, 2026Jan 19, 20278-K item 3.01
Traws PharmaTRAWfloat $9.8MStock under $1Nasdaq rule 5550(a)(2)Jul 29, 2026Jan 25, 20278-K item 3.01
MIRA PharmaceuticalsMIRAfloat $16.0MStock under $1Nasdaq rule 5550(a)(2)Jul 27, 2026Jan 25, 20278-K item 3.01
PDS BiotechnologyPDSBfloat $60.1MStock under $1Nasdaq rule 5550(a)(2)Jul 30, 2026Jan 26, 20278-K item 3.01
HumacyteHUMAfloat $280MStock under $1Nasdaq rule 5450(a)(1)Jul 31, 2026Jan 27, 20278-K item 3.01
Vistagen TherapeuticsVTGNfloat $138MStock under $1Nasdaq rule 5550(a)(2)Aug 5, 2026 (8-K filed)Feb 1, 20278-K item 3.01
Rocket OneRKTOfloat $15.4MStock under $1Nasdaq rule 5550(a)(2)Aug 6, 2026Feb 2, 20278-K item 3.01
Citius PharmaceuticalsCTXRStock under $1Nasdaq rule 5550(a)(2)Aug 17, 2026Feb 8, 20278-K item 3.01
Skye BioscienceSKYEfloat $130MStockholders' equity too lowNasdaq rule 5550(b)(1)Aug 19, 2026 (8-K filed)Feb 14, 20278-K item 3.01
BioCardiaBCDAfloat $9.7MStock under $1Nasdaq rule 5550(a)(2)Aug 19, 2026Feb 16, 20278-K item 3.01
VivoSim LabsVIVSfloat $7.5MStock under $1Nasdaq rule 5550(a)(2)Aug 17, 2026Feb 16, 20278-K item 3.01
Estrella ImmunopharmaESLAfloat $20.5MStock under $1Nasdaq rule 5550(a)(2)Aug 21, 2026 (8-K filed)Feb 16, 20278-K item 3.01
Shuttle Pharmaceuticals HoldingsSHPHfloat $4.7MLate filingNasdaq rule 5250(c)(1)Aug 28, 2026Feb 22, 20278-K item 3.01
TScan TherapeuticsTCRXfloat $56.9MStock under $1Nasdaq rule 5450(a)(1)Aug 27, 2026Feb 23, 20278-K item 3.01
Senti Biosciences HoldingsSNTIfloat $53.2MStock under $1Nasdaq rule 5550(a)(2)Aug 27, 2026Feb 23, 20278-K item 3.01
IRulya TherapeuticsIRLAfloat $64.0MStockholders' equity too lowNasdaq rule 5450(b)(1)(A)Aug 31, 2026Feb 27, 20278-K item 3.01
Nexentis TechnologiesNXTSfloat $6.4MStockholders' equity too lowNasdaq rule 5550(b)(1)Aug 31, 2026Feb 27, 20278-K item 3.01
Estrella ImmunopharmaESLAfloat $20.5MMarket value too lowNasdaq rule 5550(b)(2)Sep 8, 2026 (8-K filed)Mar 1, 20278-K item 3.01
InMed PharmaceuticalsINMfloat $3.0MStockholders' equity too lowNasdaq rule 5550(b)(1)Sep 16, 2026Mar 15, 20278-K item 3.01
Filana TherapeuticsFLNAfloat $87.0MStock under $1Nasdaq rule 5550(a)(2)Sep 17, 2026Mar 16, 20278-K item 3.01
BeyondSpringBYSIfloat $69.7MStock under $1Nasdaq rule 5550(a)(2)Sep 17, 2026Mar 16, 20278-K item 3.01
Dyadic InternationalDYAIfloat $24.2MStock under $1Nasdaq rule 5550(a)(2)Sep 25, 2026Mar 24, 20278-K item 3.01
Outlook TherapeuticsOTLKfloat $26.9MStock under $1Nasdaq rule 5550(a)(2)Sep 30, 2026 (8-K filed)Mar 24, 20278-K item 3.01
Lantern PharmaLTRNfloat $33.9MMarket value too lowNasdaq rule 5550(b)(2)Oct 1, 2026 (8-K filed)Mar 24, 20278-K item 3.01
Dare BioscienceDAREfloat $21.3MStock under $1Nasdaq rule 5550(a)(2)Sep 28, 2026Mar 29, 20278-K item 3.01
BeyondSpringBYSIfloat $69.7MMarket value too lowNasdaq rule 5550(b)(2)Sep 29, 2026Mar 29, 20278-K item 3.01
AzitraAZTRfloat $4.7MStockholders' equity too lowNYSE American rule 1003(a)(iii)Mar 13, 2026Apr 1, 20278-K item 3.01
AzitraAZTRfloat $4.7MStockholders' equity too lowNYSE American rule 1003(a)(ii)Dec 16, 2025Apr 1, 20278-K item 3.01
Canopy GrowthCGCStock under $1Nasdaq rule 5450(a)(1)Oct 14, 2026Apr 12, 20278-K item 3.01
Akebia TherapeuticsAKBAfloat $946MStock under $1Nasdaq rule 5550(a)(2)Oct 21, 2026Apr 19, 20278-K item 3.01
Milestone PharmaceuticalsMISTfloat $98.9MStock under $1Nasdaq rule 5450(a)(1)Oct 23, 2026Apr 21, 20278-K item 3.01
Actuate TherapeuticsACTUfloat $42.1MStock under $1Nasdaq rule 5450(a)(1)Oct 28, 2026Apr 26, 20278-K item 3.01
Neumora TherapeuticsNMRAfloat $63.3MStock under $1Nasdaq rule 5450(a)(1)Oct 26, 2026Apr 26, 20278-K item 3.01
VolitionrxVNRXfloat $72.9MStockholders' equity too lowNYSE American rule 1003(a)(i)Feb 9, 2026Aug 6, 20278-K item 3.01
Matinas BioPharma HoldingsMTNBfloat $4.5MStockholders' equity too lowNYSE American rule 1003(a)(iii)Jun 24, 2026Oct 2, 20278-K item 3.01
Actinium PharmaceuticalsATNMfloat $43.7MStockholders' equity too lowNYSE American rule 1003(a)(ii)Aug 14, 2026 (8-K filed)Nov 27, 20278-K item 3.01
OragenicsOGENfloat $3.1MStockholders' equity too lowNYSE American rule 1003(a)(ii)Aug 26, 2026Feb 25, 20288-K item 3.01

Data through Nov 2, 2026, the newest 8-K item 3.01 SEC Tracker has read.

Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. Not investment advice. Not affiliated with the U.S. SEC. Listing deadlines on the calendar · All screens